# CIMERLI
> **BLA761165** · Biologics License Application · Sponsor: SANDOZ INC · Approved 2022-08-02
## Drug
- **FDA Application Number:** BLA761165
- **Application type:** Biologics License Application
- **Brand name:** CIMERLI
- **Generic name:** RANIBIZUMAB-EQRN
- **Active ingredients:** RANIBIZUMAB-EQRN
- **Dosage form:** INJECTABLE
- **Route:** INJECTION
- **Marketing status:** Prescription
- **Sponsor:** SANDOZ INC
- **Manufacturer:** Coherus BioSciences Inc
- **First approval:** 2022-08-02
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761165)
---
*AI Analytics · CC0 1.0*